Building a fully integrated drug discovery company based on a translational-medicine "platform-to-product" concept to generate innovative therapies utilising significant most recent advances in stem cell biology & tissue engineering.

Initial project will focus on ophthalmic indications, i.e. retinal regeneration for e.g. Retinitis Pigmentosa.